152 related articles for article (PubMed ID: 38177097)
21. Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC.
Wang J; Zhou P; Wang X; Yu Y; Zhu G; Zheng L; Xu Z; Li F; You Q; Yang Q; Zhuo W; Sun J; Chen Z
Cell Prolif; 2019 May; 52(3):e12592. PubMed ID: 30848009
[TBL] [Abstract][Full Text] [Related]
22. Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer.
Mojtabavi Naeini M; Tavassoli M; Ghaedi K
Gene; 2018 Aug; 667():62-69. PubMed ID: 29758295
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
24. A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis.
Li J; Chen P; Wu Q; Guo L; Leong KW; Chan KI; Kwok HF
Cell Mol Life Sci; 2022 Dec; 79(12):614. PubMed ID: 36456730
[TBL] [Abstract][Full Text] [Related]
25. Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.
Xia J; Bai H; Yan B; Li R; Shao M; Xiong L; Han B
Oncotarget; 2017 Dec; 8(65):108522-108533. PubMed ID: 29312548
[TBL] [Abstract][Full Text] [Related]
26. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
[TBL] [Abstract][Full Text] [Related]
27. Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway.
Sun Q; Lu Z; Zhang Y; Xue D; Xia H; She J; Li F
Cells; 2022 Jun; 11(13):. PubMed ID: 35805163
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Botting GM; Rastogi I; Chhabra G; Nlend M; Puri N
PLoS One; 2015; 10(8):e0136155. PubMed ID: 26301867
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer.
Xie C; Jin J; Bao X; Zhan WH; Han TY; Gan M; Zhang C; Wang J
Oncotarget; 2016 Jan; 7(1):610-21. PubMed ID: 26575584
[TBL] [Abstract][Full Text] [Related]
30. Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
Kim M; Kim S; Yim J; Keam B; Kim TM; Jeon YK; Kim DW; Heo DS
Cancer Res Treat; 2023 Oct; 55(4):1134-1143. PubMed ID: 37218137
[TBL] [Abstract][Full Text] [Related]
31. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Serizawa M; Takahashi T; Yamamoto N; Koh Y
J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091
[TBL] [Abstract][Full Text] [Related]
32. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Zhang FQ; Yang WT; Duan SZ; Xia YC; Zhu RY; Chen YB
Oncotarget; 2015 Jun; 6(16):14329-43. PubMed ID: 25869210
[TBL] [Abstract][Full Text] [Related]
33. Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
Patel MR; Jay-Dixon J; Sadiq AA; Jacobson BA; Kratzke RA
J Thorac Oncol; 2013 Sep; 8(9):1142-7. PubMed ID: 23883783
[TBL] [Abstract][Full Text] [Related]
34. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
35.
Han SY; Zhao W; Han HB; Sun H; Xue D; Jiao YN; He XR; Jiang ST; Li PP
Oncotarget; 2017 Aug; 8(34):56893-56905. PubMed ID: 28915640
[TBL] [Abstract][Full Text] [Related]
36. Non-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses.
Wang HY; Hsu MK; Wang KH; Tseng CP; Chen FC; Hsu JT
Onco Targets Ther; 2016; 9():2961-73. PubMed ID: 27284246
[TBL] [Abstract][Full Text] [Related]
37. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
[TBL] [Abstract][Full Text] [Related]
38. β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer.
Xu C; Jiang ZB; Shao L; Zhao ZM; Fan XX; Sui X; Yu LL; Wang XR; Zhang RN; Wang WJ; Xie YJ; Zhang YZ; Nie XW; Xie C; Huang JM; Wang J; Wang J; Leung EL; Wu QB
Pharmacol Res; 2023 May; 191():106739. PubMed ID: 36948327
[TBL] [Abstract][Full Text] [Related]
39. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
[TBL] [Abstract][Full Text] [Related]
40. Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells.
Xu ZH; Shun WW; Hang JB; Gao BL; Hu JA
Tumour Biol; 2015 Jul; 36(7):5485-95. PubMed ID: 26036758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
